Chemo India Formulation Profile
Key Indicators
- Authorised Capital ₹ 130.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 122.36 Cr
as on 15-11-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 36.56%
(FY 2023)
- Profit 19.27%
(FY 2023)
- Ebitda 54.67%
(FY 2023)
- Net Worth 4.96%
(FY 2023)
- Total Assets 4.27%
(FY 2023)
About Chemo India Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 130.00 Cr and a paid-up capital of Rs 122.36 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Chemo India Formulation Private Limited India is Satheesh Ponugoti as COMPANY SECRETARY. Bharat Vasudevan, Maria Moran, Manuel Barro, and One other member serve as directors at the Company.
- CIN/LLPIN
U85100TG2015FTC100239
- Company No.
100239
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
13 Aug 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Chemo India Formulation?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satheesh Ponugoti  | Company Secretary | Current | |
| Ramachandra Kurumaddali | Managing Director | 13-Aug-2015 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bharat Vasudevan | Director | 06-Jun-2019 | Current |
Maria Moran  | Director | 13-Aug-2015 | Current |
Manuel Barro  | Director | 06-Jun-2019 | Current |
Financial Performance of Chemo India Formulation.
Chemo India Formulation Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.56% increase. The company also saw a substantial improvement in profitability, with a 19.27% increase in profit. The company's net worth moved up by a moderate rise of 4.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemo India Formulation?
In 2022, Chemo India Formulation had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ordain Health Care Global Private LimitedActive 13 years 5 monthsMaria Moran and Manuel Barro are mutual person
Senador Laboratories Private LimitedActive 1 year 8 monthsBharat Vasudevan and Ramachandra Kurumaddali are mutual person
- Airpharm India Private LimitedActive 28 days
Bharat Vasudevan and Ramachandra Kurumaddali are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Chemo India Formulation?
Chemo India Formulation has a workforce of 225 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemo India Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemo India Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
